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Available online 14 September 2016Objective: The current study aimed to identify the predictive values of psychological factors that are evaluated by
the Symptoms Checklist-90 (SCL-90) for acute mountain sickness (AMS).
Methods: The subjects (n = 285, non-acclimatized young Chinese men), who were recruited in July 2013, com-
pleted a case report questionnaire. In addition, their vital signs (heart rate [HR], blood pressure and pulse oxygen
saturation) were measured, and their psychological factors were examined using the SCL-90 at sea level. AMS
was diagnosed using the Lake Louise self-assessment scoring system in the morning of the second day after
their arrival at 3450 m.
Results: Of the nine factors of the SCL-90, the AMS patients (AMS score ≥ 3) were characterized by signiﬁcantly
higher scores for baseline somatization [14.0 (5.0) vs. 13.0 (3.0), p b 0.001], obsession–compulsion, depression,
anxiety and hostility compared with the non-AMS group (all p values b 0.05). Spearman's correlation analyses
revealed associations between AMS scores and somatization (r = 0.316, p b 0.001), depression, anxiety, obses-
sion–compulsion, interpersonal sensitivity, hostility, phobic anxiety, paranoid ideation and psychoticism scores
(all p values b 0.001). Although all nine factors were associated with AMS in a univariate regression (all
p b 0.05), a further adjusted logistic regression analysis indicated that only baseline somatization score (odds
ratio = 1.129, p = 0.001) was an independent predictor of AMS. Furthermore, some non-AMS often-occurred
symptoms (paresthesia, shortness of breath, reduced activity and tinnitus) were also found to be associated
with the baseline SCL-90 scores.
Conclusion: AMS is correlated with the baseline somatization score at sea level, which was measured using the
SCL-90. A higher baseline somatization score is also an independent predictor of AMS.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Acute mountain sickness (AMS) describes a syndrome that occurs
after exposure to altitudes of 2500mor higher [1,2], which is diagnosed
by Lake Louise self-score system (LLS) [2]. The incidence of AMS has
been reported to range from 10 to 85% [1,3]. AMS is a critical medical
issue that threatens tourists, workers and migrants who move from
lower altitudes to a high altitude because of its high incidence, the
resulting discomfort and the deadly risk of high-altitude cerebral
edema (HACE).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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including decreased pulse oxygen saturation (SpO2), increased HR,
evaluated cerebral hemodynamics, faster climbing speeds and higher
altitudes [6,7]. Furthermore, vasoconstriction, vasodilatation and
increased intracranial pressure or higher perfusion pressuremay partic-
ipate in the mechanisms of AMS [2,8,9]. Additionally, the physiological
or psychological activation of the sympathetic nervous system has also
been indicated as a consequence of high-altitude exposure and as a
risk factor for AMS [1,2].
Previous studies have paid particular attention to the physiological
factors associated with AMS or high-altitude headache [10], but
few of them have focused on the psychological aspects [11,12].
Although a few studies have focused on the effects of high altitude
on mental behavior [13] and psychiatric symptoms, the associations
between AMS and the associated psychiatric symptoms have not
been fully investigated. New onsets of anxiety and depression after
high-altitude exposure have been reported. Samuel J. Oliver and
colleagues investigated physiological and psychological illness
symptoms at high altitude and found that anxiety contributed to
the symptom burden when altitude was gained [11]. Furthermore,
a relationship between changes in negative mood states, including
anxiety and cognitive performance after hypoxia exposure [14]
may account for AMS symptoms. Thus, psychiatric symptoms may
be associated with or even predict AMS. In addition, AMS is
diagnosed using a subjective self-report questionnaire; thus,
psychological factors and emotional states are critical in relation to
AMS, especially for psychological and neurological clinical manifes-
tations, which include headache, dizziness and insomnia [2].
In addition to the AMS symptoms, many other complaints (non-
LLS related symptoms), such as the symptoms included in the envi-
ronmental symptoms questionnaire (ESQ-III), account for a large
proportion of the discomforts of high-altitude exposure. These
symptoms may also limit daily work and life at high altitudes,
although they are not essential for an AMS diagnosis. Therefore, it
is critical and urgent to study both the AMS-related problems and
the non-LLS related symptoms that affect individuals coming to
high altitudes from lower altitudes. We postulated that baseline psy-
chological factors would be associated with or predict AMS, and con-
ducted this study with the aim of identifying the relationships
between AMS and baseline psychological factors, as assessed using
the Symptoms Checklist-90 (SCL-90).2. Methods
2.1. Participants and procedures
2.1.1. Participants
This prospective observational study was designed to identify the
predictive values of baseline SCL-90 scores at sea level for AMS after
high-altitude exposure. The participants (285 young Chinese soldiers
on an altitude-training mission) were recruited in July 2013 at sea
level (400 m) in Chongqing and were assessed at 3450 m after a four-
day bus trip. The inclusion criteria were as follows: healthy Chinese
men between 16 and 30 years old; subjects did not take medication or
receive any intervention before ascending. However, severe headache
subjects were treated with NSAIDs or Sanlietong (Taiji medicine, Xi'an,
China) as necessary at high altitude. Subjects with any of the following
conditionswere excluded: cerebrovascular diseases, cardiovascular dis-
eases, neuro-psychosis, respiratory diseases, malignant tumors and dis-
orders of the liver or kidneys.
The study was thoroughly explained to all of the volunteers, and all
of them signed informed consent formsprior to their examinations. This
study was reviewed and approved by the Ethics Committee of Xinqiao
Hospital at the Second Clinic Medical College of the Third MilitaryMed-
ical University.2.1.2. Procedures
The baseline parameters were examined in Chongqing before their
trip using structured case report forms [i.e., age, body mass index
(BMI), smoking and alcohol consumption]. The physiological measure-
ments were conducted during routine examinations prior their travel.
Blood pressure was measured using a sphygmomanometer (HEM-
6200, OMRON, China) after a 30-min rest period. The subjects' HR and
SpO2 were also measured using a pulse oximeter (NONIN-9550, Nonin
Onyx, USA). Histories of traumatic brain injury, psychiatric disorder/
treatment, physical injuries, AMS (high-altitude headache) and high-al-
titude exposure over the past 2 years were also recorded on the case re-
port form. The primary version of the SCL-90 was used to measure the
subjects' psychiatric symptoms (Appendix 1) [15–17]. The subjects
were questioned using the SCL-90 checklist, which includes 90 items
(9 factor categories). These items were presented out of order and
were translated into Chinese[17]. Our trained physicians performed
the physiological evaluations of HR, blood pressure and SpO2.
The AMS questionnaires were performed at 3450 m (Xin Duqiao,
8:00–10:00 in the morning on the ﬁfth day after one night's rest, Fig.
1A) after the participants had completed a four-day trip from sea level
(400 m from Chongqing) via bus. AMS-related symptoms (i.e. the LLS
symptoms, headache, dizziness, gastrointestinal symptoms, difﬁculty
sleeping and fatigue/weakness) and non-LLS related symptoms were
recorded. AMS was diagnosed based on the LLS scores. Subjects whose
LLS score was 3 or higher and who had a headache were identiﬁed as
having AMS. Furthermore, many other frequently occurring non-LLS re-
lated symptoms that threaten health and daily life at high altitudes, in-
cluding lethargy, constipation, dim eyesight, dyspnea and cough, were
also queried in the case report form (as present or not present).
2.2. Statistical analysis
Normally distributed variables [i.e., age, BMI, HR, systolic blood pres-
sure (SBP), diastolic blood pressure (DBP) and SpO2] were expressed as
the mean ± standard deviation (SD). Non-normally distributed vari-
ables (the nine factors of the SCL-90) were expressed as median (quar-
tile range). The AMS+ (with AMS) and AMS− (without AMS) groups
were compared using independent samples T tests or Mann-Whitney
U-tests, as appropriate. The relationships between AMS score and each
of the aforementioned parameterswere analyzed using Spearman's cor-
relations. Univariate and adjusted logistic regressions were performed
to identify the independent variables associated with AMS (Fig. 1B,
the statistical analysis chart).
3. Results
Data were excluded if the subjects' demographic information or
other items were missing (e.g., lack of demographic information, AMS
symptoms or the sub-items of the SCL-90); totally 280 valid case report
forms and examinations were collected. The mean age and BMI of the
subjects in this study were 20.88 ± 2.42 years and 21.28 ± 2.28 kg/
m2 respectively. The percentages of participants who smoked or con-
sumed alcohol were 26.0% and 4.5% respectively. At sea level, the
mean SBP, DBP, HR and SpO2 were 112.44 ± 10.94 mmHg, 67.64 ±
8.84 mmHg, 70.20 ± 9.82 beats per min and 97.37 ± 1.15%. The inci-
dences of AMS, headache and dizziness were 24.7%, 41.9% and 50.2%
(Fig. 2A). Furthermore, the incidences of non-LLS related symptoms
were shown in Fig. 2B.
The descriptive statistics for the nine factors of the SCL-90 were
shown in Fig. 3(a–i). Most of the 280 individuals were characterized
by normal or mild scores on the nine factors of the SCL-90 (Table 1).
More speciﬁcally, 186 subjects had a somatization score between 12
and 24, and 135 had an anxiety score between 10 and 20. Mild obses-
sion–compulsion characterized a proportion of the participants (185).
Regarding depression, 119 participants reported mild depression. The
reported incidences of positive hostility (130), phobic anxiety (70)
Fig. 1. The process and ﬂowchart of the study. A: proﬁle of the ascent; B: the statistical analysis ﬂowchart.
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more, 95 individuals developed mild psychoticism (Table 1).
In terms of the demographic data, the age and BMI did not signiﬁ-
cantly differ between theAMS+andAMS− groups. Furthermore, base-
line SBP, DBP, HR and SpO2 did not differ between two groups (all p
values N 0.05). Of the nine factors of the SCL-90, somatization, obses-
sion–compulsion, depression and anxiety scores were signiﬁcantly
higher in the AMS+ group than in the AMS− group (p b 0.001). Fur-
thermore, the hostility, phobic anxiety, paranoid ideation and
psychoticism scores also showed signiﬁcant differences between two
groups (all p values b 0.001). Most of the nine factors revealed differ-
ences between the groups with and without headache and dizziness.
The differences in physiological and psychological parameters between
the groups are presented in Table 2.
Spearman's correlation analyses indicated relationships between
AMS scores and baseline BMI, somatization, obsession–compulsion,
interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety,
paranoid ideation and psychoticism scores (all p values b 0.05). Regard-
ing the nervous symptoms of AMS, headache was related to baseline
scores for somatization, obsession–compulsion, depression, hostili-
ty, phobic anxiety, paranoid ideation and psychoticism (all p
values b 0.05). Dizziness was associated with somatization, obses-
sion–compulsion, interpersonal sensitivity, depression, anxiety, hostili-
ty, paranoid ideation and psychoticism (all p-values b 0.05), though not
with phobic anxiety (p= 0.164). The associations between SCL-90 fac-
tors and AMS and its symptoms were shown in Table 3.
Univariate regressions were performed for each single variable.
However, the baselines for age, BMI, SBP, DBP, HR and SpO2were not as-
sociated with AMS (all p values N 0.05). We have also indicated thatFig. 2. Incidences of AMS-related and non-LLS related symptoms. A: incidences of Abaseline scores for somatization (p b 0.001), obsession–compulsion
(p b 0.001), interpersonal sensitivity (p = 0.015), depression (p =
0.002), anxiety (p = 0.027), hostility (p = 0.001), phobic anxiety
(p = 0.007), paranoid ideation (p = 0.004) and psychoticism (p =
0.001) were correlatedwith AMS in each univariate regression analysis.
A further adjusted logistic regression analysis was performed to identify
that the factors were independently associated with AMS; this analysis
indicated that only baseline somatization (β=0.121; OR: 1.129; 95% CI:
1.053–1.210; p = 0.001) was still a predictor of AMS independent of
other confounding factors (Table 4).
The baseline of somatization was an independent predictor for AMS.
Furthermore, we have also examined the SCL-90 characteristics of AMS
at altitude. The results showed that only higher somatization score and
depression score were independent risk factors for AMS (Appendix 2,
Tables 1A–3A).
Regarding the association between the alterations of SCL-90 and
AMS, we have also analyzed the differences and regression for AMS in
the alterations of the SCL-90. Only the change of somatization score
was associated with AMS score (r = 0.188, p b 0.001). Furthermore,
only change of somatization was still predictor for AMS (β= 0.132,
OR = 1.141, 95% CI: 1.041–1.250, p = 0.05).
In order to further identify the roles of SCL-90 in AMS, we have per-
formed the analyses between the groups with a cut-off at 4 for the LLS.
The baseline SpO2 (β=−0.563, OR= 0.569, 95% CI: 0.409–0.793, p =
0.001), somatization(β= 0.174,OR = 1.182, 95% CI: 1.046–1.353, p =
0.007) and paranoid ideation(β= 0.181,OR = 1.355, 95% CI: 1.001–
1.835, p = 0.049) scores were still independent predictors for patients
whose LLS ≥ 4. Regarding the alterations of the parameters, only chang-
es of somatization (β= 0.152, OR = 1.165, 95% CI: 1.038–1.307, p =MS and AMS-related symptoms; B: incidences of non-LLS related symptoms.
Fig. 3. Scatter plots for the nine factors of the SCL-90. Note: the nine factors of the SCL-90 were shown as medians (ranges). a. Somatization; b. Obsession–compulsion; c. Interpersonal
sensitivity; d. Depression; e. Anxiety; f. Hostility; g. Phobic anxiety; h. Paranoid ideation; and i. Psychoticism.
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p = 0.018) were independent predictor for people whose LLS ≥ 4 (Ap-
pendix 2, Tables 4A–5A).
Additionally, we investigated the incidences of non-LLS related
symptoms that commonly occurred after high-altitude exposure,Table 1
Distributions of baseline SCL-90 factors.
Without Mild Moderatea Severe
Somatization 12 12–24 24–36 ≥36
Cases (AMS) 84 (11) 186 (53) 7 (3) 3 (2)
Obsession–compulsion 10 10–20 20–30 ≥30
Cases (AMS) 86 (12) 185 (52) 9 (5) 0 (0)
Interpersonal sensitivity 9 9–18 18–27 ≥27
Cases (AMS) 125 (26) 151 (40) 4 (3) 0 (0)
Depression 13 13–26 26–39 ≥39
Cases (AMS) 155 (31) 119 (34) 6 (4) 0 (0)
Anxiety 10 10–20 20–30 ≥30
Cases (AMS) 139 (25) 135 (41) 6 (3) 0 (0)
Hostility 6 6–12 12–18 ≥18
Cases (AMS) 150 (30) 119 (32) 10 (6) 1 (1)
Phobic anxiety 7 7–14 14–21 ≥21
Cases (AMS) 205 (41) 72 (26) 3 (2) 0 (0)
Paranoid ideation 6 6–12 12–18 ≥18
Cases (AMS) 169 (36) 106 (29) 5 (4) 0 (0)
Psychoticism 10 10–20 20–30 ≥30
Cases (AMS) 182 (38) 95 (29) 3 (2) 0 (0)
Total score 90 90–160 160–200 ≥200
Cases (AMS) 101 (16) 172 (48) 6 (4) 1 (1)
a Includes the lower border.including paresthesia (24.7%), shortness of breath (26.2%), chest pain
(19.5%), tinnitus (21.7%), reduced activity (23.6%), dim eyesight
(9.0%), lethargy (14.2%), constipation (13.5%), cough (7.5%) and dys-
pnea (8.2%; Fig. 2B). The differences in SCL-90 factor scores were also
tested in relation to the four main symptoms (incidence N 20%).We ob-
served that the somatization, obsession–compulsion, interpersonal sen-
sitivity, depression, anxiety and hostility scores were signiﬁcantly
higher in individuals with paresthesia than in those without paresthe-
sia. Moreover, higher baseline scores for somatization, obsession–com-
pulsion and depression scoreswere accompanied by a greater reduction
in activity (Table 5). The differences between those with and without
shortness of breath groups in the SCL-90 factors have been identiﬁed
(Table 5).
Furthermore, the non-LLS related symptoms' characteristics of SCL-
90 at altitude has also been carried out and attached in Appendix 2
(Table 6A).4. Discussion
Themain ﬁnding of our study was that SCL-90 scores at low altitude
were associatedwith risk of AMS. In speciﬁc a tendency for somatization
was a signiﬁcant predictor of AMS. Given the subjective nature of ques-
tionnaires such as the LLS to diagnose AMS, this is noteworthy.
We observed associations between the baselines of harmful psycho-
logical symptoms as well as AMS and the associated headache, dizzi-
ness, and nervous symptoms. Additionally, we found that the baseline
somatization score is an independent predictor of AMS at 3450 m.
Table 2
Differences of psychological parameters between different groups.
AMS− AMS+ p-Value Headache− Headache+ p-Value Dizziness− Dizziness+ p-Value
SCL-90
Somatization 13.0 (3.0) 14.0 (5.0) b0.001 13.0 (2.25) 14.0 (4.0) b0.001 13.0 (3.0) 14.0 (5.0) 0.036
Obsession–compulsion 11.0 (3.0) 13.0 (4.0) b0.001 11.0 (2.0) 12.0 (3.0) b0.001 11.0 (3.0) 12.0 (4.0) 0.013
Interpersonal sensitivity 10.0 (2.0) 10.0 (3.0) 0.126 10.0 (2.0) 10.0 (3.0) 0.110 10.0 (2.0) 10.0 (3.0) 0.098
Depression 13.0 (1.0) 14.0 (3.0) 0.004 13.0 (2.0) 14.0 (3.0) 0.029 13.0 (1.0) 14.0 (3.0) 0.014
Anxiety 10.0 (2.0) 11.0 (2.0) 0.009 10.0 (2.0) 11.0 (2.0) 0.058 10.0 (1.0) 10.0 (2.0) 0.007
Hostility 6.0 (1.0) 7.0 (3.0) 0.007 6.0 (1.0) 7.0 (2.0) 0.003 6.0 (1.0) 7.0 (2.0) 0.009
Phobic anxiety 7.0 (0.0) 7.0 (1.0) 0.008 7.0 (0.0) 7.0 (1.0) 0.193 7.0 (0.5) 7.0 (1.0) 0.480
Paranoid ideation 6.0 (1.0) 6.0 (2.0) 0.020 6.0 (1.0) 6.0 (1.25) 0.010 6.0 (1.0) 6.0 (1.0) 0.059
Psychoticism 10.0 (1.0) 10.0 (3.0) 0.005 10. 0 (1.0) 10.0 (2.0) 0.002 10.0 (1.0) 10.0 (2.0) 0.081
Non-normally distributed variables (the nine factors of the SCL-90) were expressed as medians (quartile ranges).
AMS: acutemountain sickness; AMS+: (withAMS); AMS−: (withoutAMS); BMI: bodymass index; DBP: diastolic blood pressure; SBP: systolic blood pressure; SCL-90: Symptoms Check-
list-90; SpO2: pulse oxygen saturation.
Table 4
Logistic regressions for baseline parameters and AMS.
Risk factors β-coefﬁcient Odds ratio (95% CI) p-Value
Univariate regression
Age −0.011 0.990 0.882 1.110 0.857
BMI −0.032 0.968 0.852 1.101 0.625
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tors and the non-LLS related symptoms.
4.1. AMS was associated with SCL-90 factors at both altitudes
Previous studies have focused on the associations between high alti-
tude mountaineering and psychological factors [18] and have indicated
the partial association of AMSwith psychological factors throughmeta-
analysis and ﬁeld trials [19]. AMS symptoms and progression have been
also reported in normobaric hypoxia equivalent which was similar to
our study [20]. However, the predictive values of the baseline psycho-
logical factors for AMS have not been fully investigated. The current
study further reveals that individualswithAMShave higher baseline so-
matization, depression, anxiety and obsession–compulsion scores. Sub-
jects susceptible to AMS have been found to be more anxious.
Additionally, investigators have proposed the term “acute hypoxic
physiological anxiety” to describe the anxiety that occurs after the arriv-
al at altitudes and it is associated with AMS [21]. AMS patients showed
more baseline somatization symptoms score at sea level prior to high-
altitude exposure, a ﬁnding that is in accordancewith the results of pre-
vious studies on AMS symptomatology [21]. AMS severity was also pos-
itively correlated with the baseline scores for somatization, anxiety and
depression, highlighting the roles of psychological factors in theAMS di-
agnosis. It is possible that anxiety and depression reactions to high-alti-
tude exposure lead to self-reported AMS symptoms [14,22], but
subjective feelings about symptoms should not be ignored.
The emotional and behavioral changes resulting from high-altitude
exposure have been indicated in previous studies [13].We have also
identiﬁed the associations between AMS and SCL-90 at altitude. The
AMS individuals had higher somatization, depression, anxiety and ob-
session–compulsion scores, indicating that anxiety and depression
may affect the incidence of AMS. Furthermore, the average somatization
score was signiﬁcantly higher in the AMS+ group than in the AMS−
group, indicating that the AMS patients have more somatization symp-
toms, which is in accordance with the previous studies on AMSTable 3
Relationships between SCL-90 and AMS and its symptoms.
Variables AMS score Headache Dizziness
r p r p r p
SCL-90
Somatization 0.316 b0.001 0.222 b0.001 0.164 0.006
Obsession–compulsion 0.319 b0.001 0.235 b0.001 0.203 0.001
Interpersonal sensitivity 0.215 b0.001 0.104 0.083 0.150 0.012
Depression 0.274 b0.001 0.141 0.019 0.196 0.001
Anxiety 0.234 b0.001 0.111 0.064 0.201 0.001
Hostility 0.242 b0.001 0.173 0.004 0.183 0.002
Phobic anxiety 0.163 b0.001 0.079 0.188 0.083 0.164
Paranoid ideation 0.212 b0.001 0.149 0.013 0.141 0.019
Psychoticism 0.248 b0.001 0.181 0.002 0.129 0.030symptomatology [23]. The SCL-90 characteristics of AMS may be useful
for the clinical practice in treatment of AMS. However, the associations
and predictive values of baseline emotional states prior to high-altitude
exposure have not been widely investigated. Thus, the impact of base-
line psychological states before high-altitude exposure on AMS should
be of great importance. Furthermore, headache and dizziness were the
most frequently reported nervous symptoms of AMS; these symptoms
may be more likely to be affected by psychological factors than other
symptoms. Therefore, we analyzed these two symptoms in particular.
The associations between AMS and the psychological states of anxiety
and depression may be caused by their relationships with AMS-related
symptoms, such as headache and dizziness, which is partially in accor-
dance with previous reports [14,22,24]. A hypobaric chamber simula-
tion study indicated the associations between anxiety and the
symptomatology of AMS and the effects of anxiety on performance
[14]. Studies at sea level have shown a relationship between headache
(including episodic headache, chronic cluster headache and tension-
type headache) and anxiety or depression [25,26]. Further studies
have demonstrated that headaches at high altitude present with the
clinical characteristics of migraine, cluster or episodic headaches [27,
28]. The relationship between anxiety (panic attacks) and headache
has also been indicated [29], which is in accordance with our ﬁnding
that headache patients had a higher baseline anxiety level. Our previous
study also showed that somatic symptomswere associatedwith anxiety
severity after high-altitude exposure [24,30].
Dizziness is another nervous complaint of AMS that may be affected
by psychological risk factors andmay result in somatic symptoms. How-
ever, fewer studies have indicated a relationship between dizziness andSBP −0.006 0.994 0.969 1.020 0.661
DBP −0.010 0.990 0.960 1.022 0.548
HR −0.003 0.997 0.969 1.025 0.815
SpO2 −0.190 0.827 0.657 1.042 0.108
SCL-90
Somatization 0.121 1.129 1.054 1.209 0.001
Obsession–compulsion 0.163 1.177 1.078 1.286 b0.001
Interpersonal sensitivity 0.138 1.148 1.028 1.283 0.015
Depression 0.129 1.138 1.048 1.234 0.002
Anxiety 0.117 1.125 1.014 1.248 0.027
Hostility 0.220 1.246 1.090 1.423 0.001
Phobic anxiety 0.257 1.293 1.071 1.561 0.007
Paranoid ideation 0.268 1.307 1.091 1.566 0.004
Psychoticism 0.248 1.281 1.103 1.488 0.001
Adjusted regression
Somatization 0.121 1.129 1.053 1.210 0.001
Table 5
Differences of SCL-90 in four main non-AMS related symptoms.
Paresthesia− Paresthesia+ p Reduction in
activity−
Reduction in
activity+
p Shortness of
breath−
Shortness of
breath+
p Tinnitus− Tinnitus+ p
Somatization 13.0 (3.0) 14.0 (5.0) b0.001 13.0 (3.0) 14.0 (6.0) 0.011 14.0 (5.0) 14.0 (6.0) 0.043 13.0 (3.0) 14.0 (4.0) 0.067
Obsession–compulsion 11.0 (3.0) 13.0 (5.0) b0.001 11.0 (3.0) 13.0 (4.0) b0.001 12.0 (4.0) 13.0 (4.0) 0.002 11.0 (3.0) 14.0 (4.0) 0.830
Interpersonal
sensitivity
9.0 (1.0) 11.0 (2.5) b0.001 10.0 (2.0) 10.0 (4.0) 0.014 10.0 (3.0) 10.0 (4.0) 0.04 10.0 (2.0) 10.0 (2.0) 0.565
Depression 13.0 (1.0) 14.0 (4.0) b0.001 13.0 (1.0) 14.0 (3.0) b0.001 14.0 (3.0) 14.0 (3.0) 0.050 13.0 (2.0) 13.0 (3.0) 0.803
Anxiety 10.0 (1.25) 11.0 (2.5) b0.001 10.0 (1.5) 11.0 (3.0) 0.001 11.0 (2.0) 11.0 (3.0) 0.008 10.0 (2.0) 11.0 (2.0) 0.236
Hostility 6.0 (1.0) 7.0 (3.0) b0.001 6.0 (1.0) 7.0 (3.0) 0.017 7.0 (2.0) 7.0 (3.0) 0.030 6.0 (2.0) 6.0 (2.0) 0.566
Phobic anxiety 7.0 (0.0) 7.0 (1.0) 0.002 7.0 (0.0) 7.0 (1.0) 0.041 7.0 (1.0) 7.0 (1.0) 0.743 7.0 (1.0) 7.0 (1.0) 0.521
Paranoid ideation 6.0 (1.0) 6.0 (2.0) b0.001 6.0 (1.0) 7.0 (2.0) b0.001 7.0 (2.0) 7.0 (2.0) 0.003 6.0 (1.0) 6.0 (1.0) 0.540
Psychoticism 10.0 (1.0) 10.0 (2.0) 0.001 10.0 (1.0) 11.0 (2.0) b0.001 10.0 (2.0) 11.0 (2.0) 0.113 10.0 (1.0) 10.0 (2.0) 0.526
207S.-Z. Bian et al. / Physiology & Behavior 167 (2016) 202–208anxiety, although depression-induced dizziness has been reported [31,
32]. In this study, we have also observed the association between dizzi-
ness and the basic psychological parameters on the SCL-90. Although
AMS is not characterized by higher scores for interpersonal sensitivity,
the distribution was more varied in AMS+ individuals than in AMS−
individuals.
4.2. Associations between SCL-90 and non-LLS related symptoms
Many symptoms that frequently occur after high-altitude exposure
were not used for the AMS diagnosis. We further analyzed the associa-
tions between the SCL-90 factors and the non-AMS symptoms with an
incidence N20%, including paresthesia, reduced activity, shortness of
breath and tinnitus. Similar to the AMS-related symptoms, paresthesia,
reduced activity and shortness of breath were associated with signiﬁ-
cantly higher scores on most of the SCL-90 factors at baseline level, es-
pecially somatization, depression and anxiety. It is not difﬁcult to
understand that baseline psychological factors result in paresthesia
and reduced activities as a result of fear, anxiety and depression. Short-
ness of breath may be caused by somatization and anxiety about ad-
dressing hypoxia, or it may be caused by hypoxia per se [33,34].
Although paresthesia, shortness of breath and tinnitus were not includ-
ed in the diagnostic criteria, the diagnostic value of these symptoms
should be given proper attention.
Based on the discussion above, the non-AMS related symptomswith
a high incidence may be potential symptoms, and they should receive
proper attention. The non-AMS symptomatology should also been
prevented and treated promptly.
4.3. Baseline somatization score as an independent predictor of AMS
After adjusting for other parameters, only the baseline somatization
score remained an independent predictor of AMS. The sub-items of so-
matization include headache, cardiovascular, gastrointestinal and respi-
ratory symptoms. In the past several decades, most studies have given
greater attention to physiological and genetic risk factors andhave iden-
tiﬁed some valuable factors that contribute to AMS [9,35–37]. Though
anxiety has a widely demonstrated association with AMS or high-alti-
tude exposure, the baseline anxiety score was not an independent pre-
dictor of AMS in the adjusted regression. However, the baseline
somatization score predicted AMS in the adjusted analysis that exclud-
ed the effects of the confounding factors. Combinedwith the current re-
sults, somatization symptoms, emotional disorders and psychiatric
symptoms may be considered risk factors, predictors or even clinical
manifestation of AMS that need to be investigated in further studies.
4.4. Limitations
The participants in our study were all young Chinese men, which
could have generated an age or gender bias; our future studies will ad-
dress these possible biases. Another limitation of the current study isthat further detailed examinations of the mechanisms and other
methods for measuring anxiety and depression were not performed;
such examinations should be performed in future studies.
5. Conclusion
AMS is associated with the baseline somatization and other symp-
tom scores measured by SCL-90. However, only the somatization score
at baseline was a predictor of AMS independent of other confounding
factors; thus, further studies of the AMS mechanisms and possible clin-
ical applications are warranted.
Abbreviation
AMS acute mountain sickness
AMS+ (with AMS)
AMS− (without AMS)
BMI body mass index
DBP diastolic blood pressure
LLS Lake Louise self-score system
SBP systolic blood pressure
SCL-90 Symptoms Checklist-90
SpO2 pulse oxygen saturation
OR odds ratio
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